A recent study reported that the genetic and pharmacological targeting of the GRP94/LFA-1 axis strongly reduced the infiltration of Tregs in the TME, potentiating the response of CD8+ T cell effectors against the tumor [111]. Here, CD8A is linked to neoplasm.